Sumitomo Pharma Statistics

Total Valuation

Sumitomo Pharma has a market cap or net worth of 4.67 billion. The enterprise value is 5.95 billion.

Market Cap	4.67B
Enterprise Value	5.95B

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	397.29M
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	13.65%
Float	183.27M

Valuation Ratios

The trailing PE ratio is 6.65.

PE Ratio	6.65
Forward PE	n/a
PS Ratio	1.61
PB Ratio	2.53
P/TBV Ratio	n/a
P/FCF Ratio	15.54
P/OCF Ratio	13.74
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.17, with an EV/FCF ratio of 19.82.

EV / Earnings	8.48
EV / Sales	2.06
EV / EBITDA	7.17
EV / EBIT	8.60
EV / FCF	19.82

Financial Position

The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.90.

Current Ratio	1.40
Quick Ratio	0.91
Debt / Equity	0.90
Debt / EBITDA	1.99
Debt / FCF	5.50
Interest Coverage	3.59

Financial Efficiency

Return on equity (ROE) is 48.39% and return on invested capital (ROIC) is 22.11%.

Return on Equity (ROE)	48.39%
Return on Assets (ROA)	8.12%
Return on Invested Capital (ROIC)	22.11%
Return on Capital Employed (ROCE)	17.95%
Weighted Average Cost of Capital (WACC)	7.73%
Revenue Per Employee	754,638
Profits Per Employee	183,239
Employee Count	3,832
Asset Turnover	0.54
Inventory Turnover	1.95

Taxes

Income Tax	-95.47M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +136.00% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	+136.00%
50-Day Moving Average	9.57
200-Day Moving Average	10.21
Relative Strength Index (RSI)	49.12
Average Volume (20 Days)	2,238

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sumitomo Pharma had revenue of 2.89 billion and earned 702.17 million in profits. Earnings per share was 1.77.

Revenue	2.89B
Gross Profit	1.71B
Operating Income	691.35M
Pretax Income	606.70M
Net Income	702.17M
EBITDA	829.16M
EBIT	691.35M
Earnings Per Share (EPS)	1.77

Full Income Statement

Balance Sheet

The company has 365.61 million in cash and 1.65 billion in debt, giving a net cash position of -1.29 billion.

Cash & Cash Equivalents	365.61M
Total Debt	1.65B
Net Cash	-1.29B
Net Cash Per Share	n/a
Equity (Book Value)	1.84B
Book Value Per Share	4.64
Working Capital	536.63M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 339.80 million and capital expenditures -39.45 million, giving a free cash flow of 300.35 million.

Operating Cash Flow	339.80M
Capital Expenditures	-39.45M
Free Cash Flow	300.35M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.24%, with operating and profit margins of 23.91% and 24.28%.

Gross Margin	59.24%
Operating Margin	23.91%
Pretax Margin	20.98%
Profit Margin	24.28%
EBITDA Margin	28.67%
EBIT Margin	23.91%
FCF Margin	10.39%

Dividends & Yields

Sumitomo Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	0.00%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	15.04%
FCF Yield	6.43%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sumitomo Pharma has an Altman Z-Score of 1.96 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.96
Piotroski F-Score	5